<DOC>
	<DOC>NCT02393430</DOC>
	<brief_summary>To investigate the clinical effect of rebamipide in chronic gastritis patients. Patients with chronic gastritis were randomly divided into the experimental group and the control group. The experimental group were treated with rebamipide 0.1g tid and optimization of life style, and the control group were only optimized their life style for 26 weeks. Upper gastrointestinal endoscopy was performed in all patients to evaluate the severity of gastritis by modified Lanza score (MLS) and the histology by the updated Sydney system before and after treatment.</brief_summary>
	<brief_title>Clinical Effect of Rebamipide on Chronic Gastritis</brief_title>
	<detailed_description />
	<mesh_term>Gastritis</mesh_term>
	<mesh_term>Rebamipide</mesh_term>
	<criteria>With the symptoms as follow: epigastric pain, abdominal discomfort, abdominal distention, poor appetite, nausea, vomiting and so on diagnosed as chronic gastritis with endoscopic and pathological methods agree to join in this clinical trail</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>